Daisuke Nonaka

Summary

Affiliation: New York University
Country: USA

Publications

  1. pmc Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
    Alla V Ivanova
    Hematology Oncology Division, Vanderbilt Medical Center, Nashville, TN, USA
    Mol Cancer 8:91. 2009
  2. ncbi Extraneural hemangioblastoma: a report of 5 cases
    Daisuke Nonaka
    Department of Pathology, New York University Medical Center, 560 First Avenue, New York, NY 10016, USA
    Am J Surg Pathol 31:1545-51. 2007
  3. ncbi Sox10: a pan-schwannian and melanocytic marker
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 32:1291-8. 2008
  4. doi Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Cutan Pathol 35:1014-9. 2008
  5. ncbi Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mod Pathol 21:192-200. 2008
  6. ncbi Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 31:1038-44. 2007
  7. ncbi CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases
    D Nonaka
    Department of Pathology, New York University Medical Center, New York, NY 10016, USA
    Histopathology 49:381-7. 2006
  8. ncbi Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution
    Daisuke Nonaka
    Department of Pathology, National Cancer Institute, Milan, Italy
    Cancer 104:2181-8. 2005
  9. doi Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 32:1566-71. 2008
  10. ncbi Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 15:526-34. 2008

Collaborators

Detail Information

Publications39

  1. pmc Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
    Alla V Ivanova
    Hematology Oncology Division, Vanderbilt Medical Center, Nashville, TN, USA
    Mol Cancer 8:91. 2009
    ..The goal of this study was to analyze possible involvement of TUSC2 in malignant pleural mesothelioma (MPM) - an aggressive inflammatory cancer associated with exposure to asbestos...
  2. ncbi Extraneural hemangioblastoma: a report of 5 cases
    Daisuke Nonaka
    Department of Pathology, New York University Medical Center, 560 First Avenue, New York, NY 10016, USA
    Am J Surg Pathol 31:1545-51. 2007
    ....
  3. ncbi Sox10: a pan-schwannian and melanocytic marker
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 32:1291-8. 2008
    ..Our results indicate that Sox10 will serve as a more sensitive and specific marker for the diagnosis of melanocytic and schwannian tumors than S100 protein...
  4. doi Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    J Cutan Pathol 35:1014-9. 2008
    ..S100 family of proteins consists of over 20 members. We report on S100 subtypes in malignant melanomas (MMs), and BPNSTs and MPNSTs to investigate differential expression...
  5. ncbi Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mod Pathol 21:192-200. 2008
    ..In differentiated thyroid neoplasms, no significant difference in expression was seen in all the three transcription factors...
  6. ncbi Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 31:1038-44. 2007
    ..CD205 is a sensitive and specific marker for thymoma but its sensitivity to thymic carcinoma is lower than CD5 and CD117...
  7. ncbi CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases
    D Nonaka
    Department of Pathology, New York University Medical Center, New York, NY 10016, USA
    Histopathology 49:381-7. 2006
    ..CDX-2 status in pseudomyxoma peritonei (PMP) has been barely reported. The aim of this study was to investigate the clinicopathological features of 42 cases of PMP with a special emphasis on CDX-2...
  8. ncbi Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution
    Daisuke Nonaka
    Department of Pathology, National Cancer Institute, Milan, Italy
    Cancer 104:2181-8. 2005
    ..In the current study, the authors report the clinicopathologic features of patients with peritoneal diffuse malignant mesothelioma (DMM) who were treated in a uniform fashion at a single institution to assess prognostic factors...
  9. doi Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas
    Daisuke Nonaka
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Am J Surg Pathol 32:1566-71. 2008
    ....
  10. ncbi Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
    Dario Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 15:526-34. 2008
    ..We reviewed our 10-year monoinstitutional case series to identify selection factors predicting postoperative outcome...
  11. doi Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
    Dario Baratti
    Departments of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg 249:243-9. 2009
    ..To investigate outcome and prognostic factors in patients with pesudomyxoma peritonei (PMP) treated by complete cytoreduction and hyperthermic intraperitoneal chemotherapy...
  12. ncbi MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma
    Jonathan Ralston
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mod Pathol 21:1357-62. 2008
    ..MASH1 is a useful adjunct marker for differentiating small cell carcinoma of the lung from Merkel cell carcinoma...
  13. ncbi Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion
    Marcello Deraco
    Department of Surgery, National Cancer Institute, Via Venezian, 1, 20133, Milan, Italy
    Ann Surg Oncol 13:229-37. 2006
    ..We performed a prognostic analysis in a cohort of DMPM patients treated homogeneously by cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP)...
  14. pmc Genomic events associated with progression of pleural malignant mesothelioma
    Sergey V Ivanov
    Department of Cardiothoracic Surgery, Thoracic Surgery Laboratory, NYU Langone Medical Center, New York, NY, USA
    Int J Cancer 124:589-99. 2009
    ..2), FUS1 and PL6 (3p21.3), DNAJA1 (9p21.1) and CDH2 (18q11.2-q12.3). Imbalances seen by ROMA were confirmed by Affymetrix genome analysis in a subset of samples...
  15. ncbi Combined high-grade basal cell carcinoma and malignant melanoma of the skin ("malignant basomelanocytic tumor"): report of two cases and review of the literature
    Jaime Rodriguez
    Department of Pathology, National Cancer Institute, Milan, Italy
    Am J Dermatopathol 27:314-8. 2005
    ..We favor the hypothesis of a tumor with bidirectional keratinocytic and melanocytic differentiation, an exceptionally rare event...
  16. doi A study of immunohistochemical differential expression in pulmonary and mammary carcinomas
    Michael Yang
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Mod Pathol 23:654-61. 2010
    ..Caution should be taken in the interpretation of GCDFP-15 due to its occasional expression in pulmonary adenocarcinomas...
  17. ncbi Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma
    Aliza L Leiser
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 101:86-91. 2006
    ..A secondary aim was to examine if the apoptotic and cell cycle regulatory protein expression profile of uterine leiomyosarcoma is potentially useful for clinical prognostic purposes...
  18. ncbi Undifferentiated large cell carcinoma of the thymus associated with Castleman disease-like reaction: a distinctive type of thymic neoplasm characterized by an indolent behavior
    Daisuke Nonaka
    Department of Pathology, National Cancer Institute, Milan, Italy
    Am J Surg Pathol 29:490-5. 2005
    ..The first hypothesis is favored, with the added suggestion that the CD-like reaction may bear a relationship to the peculiarly indolent behavior that these tumors exhibit...
  19. doi Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities
    Sachin Gupta
    Department of Otolaryngology Head and Neck Surgery, New York University Langone Medical Center, New York, NY 10016, USA
    Arch Otolaryngol Head Neck Surg 138:227-33. 2012
    ....
  20. doi PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck
    Luc G Morris
    Head and Neck Surgery Service, New York University Cancer Institute, New York, New York
    Head Neck 30:771-5. 2008
    ..Histologic diagnosis of mucosal melanoma of the head and neck is difficult, requiring immunohistochemical stains which are less reliable than in cutaneous lesions. PNL-2 is a novel marker that has not been examined in mucosal melanoma...
  21. ncbi Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma
    Mario M Leitao
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 101:1455-62. 2004
    ..The authors also sought to assess the prognostic value of ER, PR, and AR expression in LMS...
  22. doi Differential expression of SOX2 and SOX17 in testicular germ cell tumors
    Daisuke Nonaka
    Department of Pathology, New York University Medical Center, TCH 461, 560 First Ave, New York, NY 10016, USA
    Am J Clin Pathol 131:731-6. 2009
    ..Choriocarcinomas were negative for SOX2 and SOX17. SOX2 and SOX17 expression patterns can distinguish between seminoma and embryonal carcinoma, and this distinction may be diagnostically useful...
  23. pmc Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma
    Alla V Ivanova
    Department of Cardiothoracic Surgery, Langone School of Medicine, New York University, New York, New York, USA
    Clin Cancer Res 15:2602-11. 2009
    ..We find that one of the ECM proteins, HAPLN1, is overexpressed in the majority of mesotheliomas. This study was designed to characterize the protumorigenic role of HAPLN1 in mesothelioma...
  24. ncbi Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer
    Daisuke Nonaka
    Department of Pathology, Istituto Nazionale Tumori, Milan, Italy
    Cancer Res 65:1207-12. 2005
    ..Overall, these data indicate an important role for FEZ1 in lung cancer and suggest the possibility that it may serve as a novel prognostic indicator...
  25. pmc Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
    Sylvia Adams
    Department of Medicine, Division of Medical Oncology, New York University Cancer Institute, School of Medicine, New York, NY 10016, USA
    J Immunol 181:776-84. 2008
    ..Imiquimod's adjuvant effects require further evaluation and likely need optimization of parameters such as formulation, dose, and timing relative to Ag exposure for maximal immunogenicity...
  26. doi Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure
    Myrna C B Godoy
    Department of Radiology, New York University Medical Center, 560 First Ave, IRM 236, New York, NY 10016, USA
    Chest 134:207-12. 2008
  27. ncbi NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, Italy
    Clin Cancer Res 13:7459-68. 2007
    ..The role of NKG2D receptor in antitumor immunosurveillance has not been completely clarified. We addressed this issue by investigating the involvement of this receptor in tumor-specific immunologic response in melanoma patients...
  28. ncbi Thymic mucoepidermoid carcinomas: a clinicopathologic study of 10 cases and review of the literature
    Daisuke Nonaka
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 28:1526-31. 2004
    ..Among these variants, thymic mucoepidermoid carcinomas morphologically similar to the homonymous salivary gland counterparts are particularly unusual; only 9 cases for which clinicopathologic features were available have been reported...
  29. ncbi Immunohistochemical evaluation of necrotic malignant melanomas
    Daisuke Nonaka
    Department of Pathology, New York University Medical Center, New York, NY 10016, USA
    Am J Clin Pathol 127:787-91. 2007
    ..Our study demonstrated that a combination of antibodies to HMB-45, tyrosinase, and PNL2 detected melanocytic differentiation in necrotic areas in 80% of cases...
  30. ncbi Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients
    Andrea Anichini
    Unit of Human Tumors Immunobiology and Department of Pathology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Cancer Res 66:6405-11. 2006
    ..These results suggest that quantitative variations in APM component and HLA expression in melanoma lesions from AJCC stage III and IV patients may have an effect on the clinical course of the disease...
  31. pmc Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry
    Carolina Reyes
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 27:1020-7. 2014
    ..Identifying these cases is an important step in the diagnostic workup of patients with possible hereditary leiomyomatosis and renal cell carcinoma...
  32. doi Is there a spectrum of cytologic atypia in type a thymomas analogous to that seen in type B thymomas? A pilot study of 13 cases
    Daisuke Nonaka
    Department of Histopathology, The Christie Hospital, NHS Foundation Trust, Wilmslow Road, Manchester, UK
    Am J Surg Pathol 36:889-94. 2012
    ..The various nomenclature options that could be used to name these tumors have been discussed...
  33. ncbi Cylindroma of the breast of skin adnexal type: a study of 4 cases
    Daisuke Nonaka
    Department of Pathology, National Cancer Institute, Via G Venezian 1, 20133 Milan, Italy
    Am J Surg Pathol 28:1070-5. 2004
    ..This is the second reported case of this hereditary syndrome with extracutaneous manifestations and the first case in which the breast is involved...
  34. ncbi Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
    D Baratti
    Department of Surgery, National Cancer Institute, Milan, Italy
    Ann Surg Oncol 14:2790-7. 2007
    ..The aim of the current study was to review our experience with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in these clinical settings...
  35. ncbi Congenital fibrosarcoma with metastasis in a fetus
    Daisuke Nonaka
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Pediatr Dev Pathol 7:187-91. 2004
    ..Metastatic tumors were identified at autopsy when the pregnancy was terminated 3 wk later. English literature of metastatic congenital fibrosarcoma was also reviewed...
  36. ncbi p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas
    S E Anderson
    Department of Developmental Chemotherapy, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, USA
    Int J Gynecol Cancer 16:849-53. 2006
    ..EGFR was not commonly expressed in ULMS. These uniquely expressed markers may assist in stratifying patients by survival and identify novel therapeutic markers. Clearly, further investigation is needed...
  37. ncbi A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients
    Lorenzo Pilla
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Immunol Immunother 55:958-68. 2006
    ..Clinical activity was limited to SD. However, both immunological and clinical responses were not improved as compared with those recorded in a previous study investigating HSPPC-96 monotherapy...
  38. ncbi Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles
    Roberta Mortarini
    Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy
    Cancer Res 65:3428-36. 2005
    ..These data suggest that LIGHT constitutively expressed in human melanoma cells and microvesicles may contribute to regulate T-cell responses to tumor cells...
  39. ncbi Sebaceous gland carcinoma of the scalp: case report and review of the literature
    Murtaza Rizvi
    Department of Surgical Services, York Hospital, York, Pennysylvania, USA
    J Otolaryngol 32:64-8. 2003